Pharmaceutical Technology
APRIL 18, 2023
The regulatory approval for the expanded indication was based on the data obtained from the pivotal Phase III PROGRESS trial, which assessed the efficacy, tolerability and safety of oral Qulipta 60mg once daily (QD) in adult patients with chronic migraine. The 60mg dose is indicated for chronic migraine patients.
The Pharma Data
JULY 29, 2021
are living with spasticity across a variety of neurologic conditions — BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity. Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. million adults in the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 18, 2021
June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.
The Pharma Data
SEPTEMBER 10, 2021
” Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA ® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX ® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.
The Pharma Data
MARCH 30, 2021
2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. . IMPORTANT SAFETY INFORMATION.
The Pharma Data
APRIL 7, 2021
“Our strong presence at AAN reflects our expanded portfolio of approved and investigational treatments designed to address a wide range of complicated, often debilitating neurological disorders,” said Michael Gold , M.D., vice president, neuroscience development, AbbVie. About BOTOX ®. Indications.
The Pharma Data
NOVEMBER 2, 2020
Now is the ideal time to develop nabiximols in the U.S. In addition to MS spasticity, GW expects to develop nabiximols in spinal cord injury spasticity. There are a few medications approved to treat spasticity, including the generic baclofen and Botox. It also forced the U.S.
Expert insights. Personalized for you.
130 
Let's personalize your content